Improving decision-making for chronic kidney disease patients and their caregivers
Official title: An Optimization Trial of a Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
Run by University of Alabama at Birmingham · NCT06173323 · Data updated 2026-11-12
This study is testing a program to help patients with stage 4 chronic kidney disease and their caregivers make better health decisions together.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 128 (estimated) |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Status | Recruiting |
| Started | September 16, 2024 |
| Main results expected | March 31, 2028 |
| Study ends | March 31, 2028 |
| Registry record updated | January 26, 2026 |
| Trial ID | NCT06173323 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a documented diagnosis of stage 4 chronic kidney disease who have an enrolled caregiver.
✕Probably not a fit
Patients receiving hospice care, dialysis, or those with severe mental illness or other significant health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the decision-making skills of patients with stage 4 chronic kidney disease (CKD) and their caregivers through a structured intervention. Utilizing a Multiphase Optimization Strategy (MOST), 64 dyads will be randomized to receive various components of decision partnering training, which includes caregiver coaching and communication training. The goal is to empower both patients and caregivers to navigate health-related decisions more effectively, particularly in the context of CKD management and end-of-life choices. The intervention is designed to address the unique challenges faced by historically excluded populations, particularly Black CKD patients and their families.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the decision-making process and overall well-being of CKD patients and their caregivers.
How similar studies have gone: While there have been few interventions focusing on decision-making in CKD that include caregivers, this approach is innovative and aims to fill a significant gap in existing research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 1. Age ≥18; 2. EMR documented diagnosis of stage 4 CKD (2 eGFR 29-15 within 90 days); 3. Ability to speak and read English and complete baseline questionnaires; 4. Patients must have an enrolled caregiver Exclusion Criteria: * Patients 1. Receiving hospice; 2. Receiving dialysis; 3. Medical record documentation of active unmedicated severe mental illness, moderate-severe dementia, suicidal ideation, uncorrected hearing loss, and active substance abuse. Inclusion Criteria: * Caregivers 1. Age ≥18; 2. Self-endorsing or identified by the patient as a relative, friend, or partner that has a close relationship with you and who assists you with your medical decisions and who may or may not live in the same residence as you and who is not paid for their help 3. Caring for a patient with CKD; 4. Ability to speak and read English and complete baseline questionnaires; 5. Caregivers must have an enrolled patient. Exclusion Criteria: * Caregivers 1) Self-reported unmedicated mental illness, Moderate-severe dementia, active suicidal ideation, uncorrected hearing loss, or active substance abuse ascertained by scripted study introduction questioning.
Where it's running
-
Shena Gazaway
Birmingham, Alabama, United States Recruiting
Study contacts
- Principal investigator: Shena Gazaway, PhD — University of Alabama at Birmingham
- Study coordinator: Shena Gazaway, Phd, RN
- Email: gazaways@uab.edu
- Phone: 205-975-5704
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational look at how Kremezin works in adults with advanced chronic kidney disease
This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.
-
Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China
This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
-
Arterial stiffness in children and young people with CKD and hypertension
This study will test whether arterial stiffness is higher in children and young people with chronic kidney disease and high blood pressure compared with their peers, using a one-time assessment and follow-up for those with high BP.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.